YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection

YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma” or the “Company”) today announced that the United States Patent and Trademark Office has issued it a patent covering the Company’s PIKA YS-HBV-002, an immunotherapeutic vaccine designed to treat patients suffering from chronic hepatitis B virus (“HBV”) infection.